Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: A randomized, double-blind, active-controlled trial

Journal of Medical Virology

Volumn 84, Issue 8, 2012, Pages 1224-1232

  Tyring, Stephen K ^a   Plunkett, Stephanie ^b   Scribner, Anita R ^c   Broker, Robert E ^d   Herrod, John N ^e   Handke, Lane T ^f   Wise, John M ^g   Martin, Paul A ^h  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b J Lewis Research/First Med East   (United States)

^c Diagnostic Clinic of Longview   (United States)

^d Hillcrest Clinical Research   (United States)

^e Cochise Clinical Research ^*  (United States)

^f Fallbrook Family Health Center   (United States)

^g Bozeman Urgent Care Center   (United States)

^h Providence Health Partners Centers for Clinical Research   (United States)

Author keywords

Clinical trial; Herpes zoster; Shingles; Valacyclovir; Valomaciclovir

Indexed keywords

GLUCOSE; PLACEBO; VALACICLOVIR; VALOMACICLOVIR;

ABDOMINAL CRAMP; ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; FEMALE; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; HEADACHE; HERPES ZOSTER; HUMAN; IMMUNOCOMPETENCE; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHYSICAL EXAMINATION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN PAIN; SORE THROAT; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTIGO; VOMITING;

ACUTE DISEASE; ACYCLOVIR; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; GUANINE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOCOMPETENCE; MALE; MIDDLE AGED; TREATMENT OUTCOME; VALINE;

EID: 84862686002     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23329     Document Type: Article

References (18)

1. Abele G, Karlström A, Harmenberg J, Shigeta S, Larsson A, Lindborg B, Wahren B. 1987. Inhibiting effect of (R, S)-9-[4-hydroxy-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture. Antimicrob Agents Chemother 31: 76-80.
2. Abele G, Cox S, Bergman S, Lindborg B. 1991. Antiviral activity against VZV and HSV type 1 and type 2 of the (+) and (-) enantiomers of (R, S)-9-{4-hydroxy-2- (hydroxymethyl)butyl}guanine], in comparison to other closely related acyclic nucleosides. Antivir Chem Chemother 2: 163-169.
3. Akesson-Johansson A, Harmenberg J, Wahen B, Linde A. 1990. Inhibition of human herpesvirus 6 replication by 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (2HM-HBG) and other antiviral compounds. Antimicrob Agents Chemother 34: 2417-2419.
4. Andrei G, Snoeck R, Reymen D, Liesnard C, Goubau P, Desmyter J, De Clercq E. 1995. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur J Clin Microbiol Infect Dis 14: 318-329.
5. Baker DA. 2002. Valacyclovir in the treatment of genital herpes and herpes zoster. Expert Opin Pharmacother 3: 51-58.
6. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. 1995. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 39: 1546-1553.
7. De Clercq E, Field HJ. 2006. Antiviral prodrugs-The development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 147: 1-11.
8. Fleming TR, Powers JH. 2008. Issues in noninferiority trials: The evidence in community-acquired pneumonia. Clin Infect Dis 47: S108-S120.
9. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. 2005. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 20: 748-753.
10. Lake-Bakaar DM, Abele G, Lindborg B, Soike KF, Datema R. 1988. Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R, S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug. Antimicrob Agents Chemother 32: 1807-1812.
11. Lowe DM, Alderton WK, Ellis MR, Parmar V, Miller WH, Roberts GB, Fyfe JA, Gaillard R, Ertl P, Snowden W, Littler E. 1995. Mode of action of [(R)-9-{4-hydroxy-2- (hydroxymethyl)butyl}guanine] against herpesviruses. Antimicrob Agents Chemother 39: 1802-1808.
12. Ng TI, Shi Y, Huffaker HJ, Kati W, Liu Y, Chen CM, Lin Z, Maring C, Kohlbrenner WE, Molla A. 2001. Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine. Antimicrob Agents Chemother 45: 1629-1636.
13. Rimland D, Moanna A. 2010. Increasing incidence of herpes zoster among Veterans. Clin Infect Dis 50: 1000-1005.
14. Soike KF, Bohm R, Huang J, Oberg B. 1993. Efficacy of (-)-9-[4-hydroxy-2- (hydroxymethyl)butyl]guanine in African green monkeys infected with simian varicella virus. Antimicrob Agents Chemother 37: 1370-1372.
15. Soike KF, Alder J, Marsh K, Shiosaki K. 1997. Antiviral efficacy of orally administered ABT-606, a diester prodrug of H2G in African green monkeys infected with simian varicella virus [abstract H-55]. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington DC: American Society of Microbiology.
16. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. 2000. Antiviral therapy for herpes zoster: Randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 9: 863-869.
17. United States Food and Drug Administration (FDA). 1995. Summary basis of approval (valtrex, herpes zoster). Silver Spring, MD: FDA. NDA, pp 20-487.
18. Whitley RJ. 2009. A 70-year-old woman with shingles: Review of herpes zoster. JAMA 302: 73-80.